Gene Therapy for Spinal Muscular Atrophy (SMA): Spinraza and Beyond

Disease Mechanism

SMA is caused by homozygous loss-of-function mutations in SMN1, leading to deficiency of survival motor neuron (SMN) protein and progressive motor neuron degeneration.

Spinraza (Nusinersen)

  • Mechanism: Antisense oligonucleotide that modifies SMN2 splicing to increase functional SMN protein.
  • Administration: Intrathecal injection (loading doses at days 0, 14, 28, 63; then every 4 months).
  • Efficacy: Clinical trials show improved motor milestones, survival, and quality of life across SMA types.
  • Safety: Generally well-tolerated; common adverse events include headache, back pain, post-lumbar puncture syndrome.
  • Cost: Over $750,000 first year; patient assistance programs exist.

Emerging Therapies

  • Onasemnogene abeparvovec (Zolgensma): AAV9-mediated SMN1 gene replacement via one-time IV infusion.
  • Risdiplam (Evrysdi): Oral small-molecule SMN2 splicing modifier.
  • Future: Next-generation gene editing, neuroprotective agents, and combination regimens.

Early diagnosis through newborn screening and prompt treatment initiation maximize benefit. Multidisciplinary SMA clinics optimize care coordination.

Genetic Disorders - Related Articles